Dr.JAYARAM MEHER, M21571
Aim-To study comparative efficacy of alcaftadine 0.25% vs olopatadine 0.2% in SAC. Methods: prospective study involving 128 patients diagnosed with SAC assigned into 2 groups. 1st group received olopatadine ,2nd group alcaftadine in 1 eye & placebo drop in c/l eye used twice daily. Full ophthalmological examination done. Review on 3rd, 7th &15th day after T/t initiation. Signs &symptoms evaluated using a 3-point scale. Results:On day 3, ocular symptoms improved in alcaftadine group. F.b sensation, papillary reaction not subsided in olopatadine group. At day 3 70% cases improved, at day 7 all features subsided in alcaftadine group, but in olopatadine group f.b sensation and papillary reaction remained in 12%. At day 15, all features improved in all pts in both groups. Eyes with placebo t/t didn’t show significant improvement at day 3,7,15. Conclusion: Alcaftadine appears to be better than olopatadine 0.2% in improving ocular symptoms at 7 day followup.
Leave a Comment